| Wednesday 05/07/2023 |
| 07:30 | Registration |
|
| 08:45 | Opening Ceremony |
Mrs Mady DORCHIES-BRILLON (RÉGION HAUTS-DE-FRANCE, LILLE, France)
Prof. Franck DUMEIGNIL (UNIVERSITY OF LILLE, Lille, France)
Dr Jean-Yves ORTHOLAND (EDELRIS, Lyon, France)
Prof. Nicolas WILLAND (INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France) |
| Session 1: Hit Finding |
|
| Session chair |
Dr Priscille BRODIN
(INSERM - UNIVERSITÉ DE LILLE, Lille, France) |
| 09:15 | PL01 - Fragment-based Design of Methionine Adenosyl Transferase (MAT2a) Inhibitors with Anti-tumour Effect |
Dr Marianne SCHIMPL
(ASTRAZENECA, Cambridge, United Kingdom) |
| 09:50 | PL02 - Identification of CDK8 Inhibitors as Inducers of Tendon Cell Differentiation through Phenotypic Screening and Chemoproteomics |
Dr Jean-Baptiste LANGLOIS
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 10:25 | Coffee Break sponsored by Merck, Networking & Exhibition |
|
| Session 2: New Avenues in Drug Discovery Chemistry |
|
| Session chair |
Dr Jean QUANCARD
(NOVARTIS, Basel, Switzerland) |
| 10:55 | PL03 - Discovery of Novel Microbiome-Sparing Antibiotics with Activity Against Gram-Negative Pathogens |
Prof. Paul J. HERGENROTHER
(UNIVERSITY OF ILLINOIS, Urbana, United States) |
| 11:30 | PL04 - Electrochemistry in High-Throughput |
Dr Nessa CARSON
(ASTRAZENECA, Macclesfield, United Kingdom) |
| 12:05 | OC01 - Experiences from CETSA Screens for Hit Discovery versus Challenging Targets |
Dr Alice LANNE
(ASTRAZENECA, Macclesfield, United Kingdom) |
| 12:25 | Lunch, Networking & Exhibition |
|
| 13:15 | Poster Session I (posters with odd numbers), Networking & Exhibition |
|
| Session 3: New Molecular Landscapes in Drug Discovery |
|
| Session chair |
Dr Nicolas GEORGE
(AQEMIA, Paris, France) |
| 14:45 | PL05 - Stabilizing Relevant GPCR Conformations to Discover Therapeutic Antibodies |
Dr Christel MENET
(CONFO THERAPEUTICS, Brussels, Belgium) |
| 15:20 | PL06 - LipMete (Lipophilic Metabolism Efficiency) as a Simple Guide for Half-Life and Dosing Regimen Prediction of Oral Drugs |
Dr Antonia F. STEPAN
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland) |
| 15:55 | OC02 - Potential of Chloroalkene as Amide Bond Isostere |
Prof. Tetsuo NARUMI
(SHIZUOKA UNIVERSITY, Hamamatsu, Japan) |
| 16:15 | OC03 - Scaffold out of the Blue: Azulenes for Medicinal Chemistry |
Dr Jörg KLEY
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany) |
| 16:35 | Coffee Break, Networking & Exhibition |
|
| Session 4: Late-Breaking Topics: First Disclosures of Clinical Candidates and Cases Studies |
|
| Session chair |
Prof. Benoit DEPREZ
(INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France) |
| 17:05 | PL07 - Discovery of GLPG3970, A First-in-class SIK2/SIK3 Inhibitor Evaluated in Clinical Trials for the Treatment of Autoimmune and Inflammatory Diseases |
Dr Christophe PEIXOTO
(GALAPAGOS, Romainville, France) |
| 17:40 | PL08 - Leucettinib-21, A DYRK1A Inhibitor Drug Candidate Aiming at the Correction of Cognitive Disorders in People with Down Syndrome or Alzheimer’s Disease |
Dr Laurent MEIJER
(PERHA PHARMACEUTICALS, Roscoff, France) |
| 18:15 | PL09 - Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection |
Dr Wei ZHU
(CHINA INNOVATION CENTER OF ROCHE (CICOR), Shanghai, China) |
| 18:50 | Welcome Reception |
|
| 20:30 | End of the Day |
|
| Thursday 06/07/2023 |
| Session 5: Evotec Prize for Excellence in Molecular Design |
|
| Session chairs |
Dr Jean-Yves ORTHOLAND (EDELRIS, Lyon, France)
Dr Christophe BOLDRON (EVOTEC, Toulouse, France) |
| 08:45 | PL10 - Modulation of Protein – Protein Interactions by Means of Peptidomimetics |
Prof. Steven BALLET
(VRIJE UNIVERSITEIT BRUSSEL, Brussels, Belgium) |
| 09:45 | Session 6: Neurodegenerative Diseases |
|
| Session chair |
Prof. Patricia MELNYK
(INSERM - UNIVERSITÉ DE LILLE, Lille, France) |
| 09:45 | PL11 - Structural Biology Supporting Medicinal Chemistry of Purine Receptors |
Prof. Christa MÜLLER
(UNIVERSITY OF BONN, Bonn, Germany) |
| 10:20 | OC04 - Unravelling the Potential of the Type 2 Lysophosphatidic Acid Receptor (LPA2) for Central Nervous System Pathologies |
Prof. Silvia ORTEGA GUTIERREZ
(COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain) |
| 10:40 | Coffee Break, Networking & Exhibition |
|
| Session 7: Covalent Inhibitors in Drug Discovery |
|
| Session chair |
Dr Didier ROCHE
(EDELRIS, Lyon, France) |
| 11:10 | PL12 - Development of SARS Coronavirus 3CL Protease Inhibitors with an Electrophilic aryl-ketone Warhead |
Prof. Yoshio HAYASHI
(TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES, Tokyo, Japan) |
| 11:45 | PL13 - Inhibitors of the Mitochrondrial Sirtuins 3 and 5 |
Prof. Christian A. OLSEN
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark) |
| 12:20 | Lunch, Networking & Exhibition |
|
| 12:35 | SCHRÖDINGER WORKSHOP (optional but subject to prior registration)
Augmenting Medicinal Chemistry with Digital Chemistry: a CDK2 Inhibitor Design Challenge |
|
| 13:15 | Poster Session II (posters with even), Networking & Exhibition |
|
| Session 8: Next Generation of Anti-infective Agents |
|
| Session chair |
Dr Baptiste VILLEMAGNE
(INSERM - UNIVERSITÉ DE LILLE, Lille, France) |
| 14:45 | PL14 - BacPROTACs Mediate Targeted Protein Degradation in Bacteria |
Prof. Francesca Ester MORREALE
(THE FRANCIS CRICK INSTITUTE, London, United Kingdom) |
| 15:20 | OC05 - Tackling LysS, a New Target for Tuberculosis |
Dr Laura A.T. CLEGHORN
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom) |
| 15:40 | OC06 - Historical Evolution and Lessons Learned from an RSV Non Nucleosides Polymerase Inhibitor Program |
Dr Sandrine GROSSE
(JANSSEN, Beerse, Belgium) |
| 16:00 | Coffee Break, Networking & Exhibition |
|
| 16:30 | PL15 - Metallo-Enzymes - From Functions to Drugs |
Prof. Christopher J. SCHOFIELD
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
| Session 9: Small Molecules for Immunooncology or Autoimmunity |
|
| Session chair |
Prof. Rebecca DEPREZ-POULAIN
(INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France) |
| 17:05 | PL16 - Discovery of the Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist with Therapeutic Potential in Autoimmune Diseases |
Dr Eva CAROFF
(IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland) |
| 17:40 | OC07 - Discovery of an Oral, Rule-of-5 Compliant, IL-17A Protein-Protein Interaction Modulator (IL-17A PPIm) for the Treatment of Psoriasis and other Inflammatory Diseases. |
Dr Mark D. ANDREWS
(LEO PHARMA, Ballerup, Denmark) |
| 18:00 | OC08 - Small-Molecule Inhibitor Targeting PD-1/PD-L1 Interaction Restores T-Cell Function |
Prof. Helena FLORINDO
(IMED - UNIVERSITY OF LISBON, Lisbon, Portugal) |
| 18:20 | End of the Day |
|
| 20:00 | Symposium Banquet (subject to prior registration) |
|
| Friday 07/07/2023 |
| Session 10: Beyond PROTACS |
|
| Session chair |
Dr Guillaume LACONDE
(OXELTIS, Montpellier, France) |
| 08:45 | PL17 - Bifunctional Molecules for Exploring and Treating Human Disease |
Prof. David SPIEGEL
(YALE UNIVERSITY, New Haven, United States) |
| 09:20 | PL18 - A Tricycle Journey to in vivo Degraders of the Oncogenic Transcription Factor BCL6 |
Prof. Swen HOELDER
(THE INSTITUTE OF CANCER RESEARCH, Sutton, United Kingdom) |
| 09:55 | PL19 - Expansion of the Druggable Genome through Rational Approaches to Molecular Glue Discovery |
Dr Rohan BECKWITH
(NEOMORPH INC., San Diego, United States) |
| 10:30 | Coffee Break, Networking & Exhibition |
|
| Session 11: Galapagos Award For Drug Discovery Chemistry |
|
| Session chair |
Dr Jean-Yves ORTHOLAND (EDELRIS, Lyon, France)
Dr Sandrine VENDEVILLE (GALAPAGOS, Beerse, Belgium) |
| 11:00 | PL20 - Peptide, A Manifesto |
Prof. Philippe KAROYAN
(SORBONNE UNIVERSITÉ, VILLEBON SUR YVETTE, France) |
| 12:00 | Closing Ceremony |
|
| 12:30 | End of the Symposium |
|
